Rothschild Investment Corp IL decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.8% during the second quarter, Holdings Channel reports. The firm owned 33,889 shares of the biopharmaceutical company’s stock after selling 7,320 shares during the period. Rothschild Investment Corp IL’s holdings in Gilead Sciences were worth $2,399,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in the company. Keel Point LLC raised its stake in shares of Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 11 shares during the period. West Oak Capital LLC raised its stake in shares of Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the period. Westover Capital Advisors LLC raised its stake in shares of Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 46 shares during the period. Abner Herrman & Brock LLC raised its stake in shares of Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 50 shares during the period. Finally, ARS Investment Partners LLC raised its stake in shares of Gilead Sciences by 0.9% in the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 50 shares during the period. Hedge funds and other institutional investors own 74.02% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) traded up 0.67% on Tuesday, reaching $73.30. 2,143,580 shares of the company’s stock traded hands. The firm has a market capitalization of $95.72 billion, a P/E ratio of 7.96 and a beta of 1.21. The company’s 50-day moving average is $72.43 and its 200-day moving average is $68.75. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $82.10.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the company earned $3.08 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.86%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is currently 22.58%.

ILLEGAL ACTIVITY WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.watchlistnews.com/rothschild-investment-corp-il-has-2-40-million-stake-in-gilead-sciences-inc-gild/1491687.html.

A number of brokerages recently issued reports on GILD. Jefferies Group LLC restated a “hold” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 11th. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 target price on the stock. in a research report on Tuesday, April 25th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 3rd. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Finally, BMO Capital Markets restated a “hold” rating and set a $76.00 target price (up previously from $75.00) on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Twelve investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $80.31.

In related news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the transaction, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 206,666 shares of company stock valued at $15,223,184. Corporate insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.